Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.47, read 2026-10-27
Ethical passes the values gate
Price68.82 USD
Fair value100.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Accumulation66.57+3.4% to today ✓Markdown gives way to Accumulation after a 5% rise in 3 weeks
2026-10-02Read Markdown63.37+8.6% to today Distribution gives way to Markdown after a 16% slide in 5 weeks
2026-08-26Read Distribution75.38-8.7% to today ✓Accumulation gives way to Distribution after a 12% slide in 4 weeks
2026-07-26Read Accumulation85.67-19.7% to today Distribution gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Diebold Nixdorf, Incorporated holds its Accumulation at $68.82. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-10-26
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$68.82
Valuation
22.50 trailing · 9.71 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.19
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
24.35%
Below 33%
Interest-bearing debt is just 24.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.75%
Below 33%
Cash held in interest-bearing accounts and securities is 0.8% of assets, under the one-third limit.
Pass
Receivables
25.38%
Below 49%
Money owed to the company is 25.4% of assets, under the 49% limit.
Pass
Revenue purity
0.23%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Diebold Nixdorf, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DBD's ethical verdict changes
Today DBD passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-26 screen. The gold marker is the market price at the same screen. A 46.7% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus Strong Buy. The average target sits +45% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Quiet machines still power daily banking and shopping
Every time someone pulls cash from an ATM or scans groceries at a self-checkout, the hardware and software must work without fuss. Diebold Nixdorf supplies those systems across banks and retailers worldwide through its two core segments. Revenue is expanding at 6 percent, yet the business posts only a 3 percent profit margin and an 11 percent return on equity, which leaves little room for error.
The shares trade at 12.6 times forward earnings with a 17 percent gap to our fair value of 100 dollars, and the ethical screen is cleared. Three analysts see the same 100-dollar median target, yet our opportunity rating stays at none because the growth and returns do not clear the threshold for conviction.
Unknown competitive protection and exposure to capital-spending cycles at banks and retailers add real uncertainty. Thin margins can shrink quickly if hardware demand softens or if larger rivals win renewals. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DBD trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$68.16+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$68.16+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$68.16+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$68.16+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$68.16+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$68.16+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$68.16+2.4%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$63.67+0.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98.
2026-10-02Markdown · changed$63.37-15.9%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 59%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (3 analysts) rates it none, with a mean price target of $98.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
